Current management and emerging treatment strategies for multiple myeloma

  • LEI Matthew
    Department of Pharmacy, Massachusetts General Hospital
  • KIM E. Bridget
    Department of Pharmacy, Massachusetts General Hospital
  • BRANAGAN Andrew
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center
  • LOU Uvette
    Department of Pharmacy, Massachusetts General Hospital
  • ZEMEL Melanie
    Medical School for International Health, Ben-Gurion University of the Negev
  • RAJE Noopur
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center

この論文をさがす

抄録

<p>Multiple myeloma is a malignant plasma cell neoplasm that is incurable despite significant progress in treatment over the past several decades. The incorporation of novel agents and combinations into the MM treatment paradigm has resulted in improved survival and tolerability, as well as deeper responses including achieving a minimal residual disease negative state. The addition of new treatment options and combinations has added complexity in treatment selection for myeloma patients. The current strategy for newly diagnosed myeloma involves induction, consolidation, and maintenance therapy. However, nearly all myeloma patients will develop refractory disease. This highlights the need for more effective therapies targeting the myeloma cells and their microenvironment. In this article, we summarize current management of transplant eligible and ineligible newly diagnosed patients in both the upfront and relapsed refractory setting, highlighting risk adapted strategies. We also summarize emerging therapies, such as immune and targeted approaches, as well as drugs with novel mechanisms of action. Emerging strategies offer individualized treatment options and may ultimately offer the possibility of a cure for myeloma patients.</p>

収録刊行物

  • 臨床血液

    臨床血液 60 (9), 1243-1256, 2019

    一般社団法人 日本血液学会

詳細情報

問題の指摘

ページトップへ